Johnson & Johnson announced that the European Commission has approved Edurant for the treatment of HIV-1 infection in adults and children weighing at least 25 kg without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor class and with a viral load less than or equal to 100,000 HIV-1 RNA copies/ml. To support expanded pediatric use, new 2.5 mg dispersible tablets have been developed for weight-adjusted dosing in children 2 to less than 18 years of age, weighing at least 14 kg and less than 25 kg.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson says Impella ECP met primary endpoint in high-risk PCI study
- Johnson & Johnson’s Tremfya shows efficacy in Crohn’s disease Phase 3 study
- Johnson & Johnson reports results from Phase 3b SPECTREM study
- Halozyme provides update following EPO decision to revoke Darzalex patent
- Kenvue price target raised to $27 from $24 at BofA